Skip to main content

Table 2 Hazard ratios for time to the composite outcome (non-fatal severe CV event or all-cause death), comparing exposed periods in the 365 days following the onset of an first exacerbation of COPD (moderate or severe/ moderate/ severe) to the non-exposure period

From: Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands

Time period

No. of first CV events of any type

Person years of follow-up

Unadjusted

HR (95% CI)

Adjusted*

HR (95% CI)

While patient is unexposed

 Prior to the first exacerbation or > 365 days since exposure

732

21,764

1

1

After the onset of an exacerbation (moderate or severe)

 1–7 days

82

98

24.1 (19.0–30.5)

15.3 (11.8–20.0)

 8–14 days

38

96

11.0 (7.9–15.4)

7.0 (4.9–10.0)

 15–30 days

51

204

7.4 (5.5–9.9)

4.8 (3.5–6.5)

 31–180 days

124

1376

2.7 (2.2–3.3)

1.9 (1.5–2.3)

 181–365 days

65

1069

1.8 (1.4–2.4)

1.3 (1.0–1.8)

After the onset of a moderate exacerbation

 1–7 days

10

76

3.7 (2.0–6.9)

2.5 (1.3–4.8)

 8–14 days

11

75

4.0 (2.2–7.3)

2.7 (1.5–5.0)

 15–30 days

21

161

3.9 (2.5–6.0)

2.6 (1.7–4.2)

 31–180 days

80

1099

2.2 (1.7–2.8)

1.6 (1.3–2.1)

 181–365 days

46

859

1.6 (1.2–2.2)

1.3 (0.9–1.7)

After the onset of a severe exacerbation

 1–7 days

72

22

91.5 (71.3–117.3)

48.6 (36.9–64.0)

 8–14 days

27

21

37.2 (25.2–54.8)

20.0 (13.3–30.1)

 15–30 days

30

43

20.1 (13.9–29.1)

11.3 (7.7–16.5)

 31–180 days

44

275

4.8 (3.6–6.6)

2.8 (2.0–3.8)

 181–365 days

19

209

2.8 (1.8–4.4)

1.6 (1.0–2.6)

  1. CI: Confidence interval; CV: Cardiovascular; HR: Hazard ratio
  2. *Adjusted for baseline covariates: year of cohort entry, age, sex, socio-economic status, obesity, type 2 diabetes, disorders of lipoprotein metabolism and other lipidaemias, ischaemic heart disease, hypertensive disease, heart failure, venous thromboembolism, cerebrovascular disease, arrhythmia, asthma, chronic kidney disease or renal failure, severe mental illness and/or anxiety disorder, and time-dependent covariates: number of GP visits in the last 12 months, number of prior moderate or severe exacerbations, long-acting and short-acting inhaled COPD drug use, roflumilast and/or theophylline, cardiac drugs and metabolic drugs